Fundamentals II: Emerging Role of HER2- and TROP2-Targeted ADCs in NSCLC—What APPs Need to Know

CE Information

0.5 contact hours (0.5 pharmacology)

Completion Time

1 hour

Available Until

May 11, 2025

Posted By

PCE

Ready to start this activity?

Navigate

Overview

Specialties

Adult, Family, Oncology, and Women's Health

Subspecialties

Oncology

Clinical Topics

Oncology and Women's Health

Watch an on-demand webcast where an expert discusses what advanced practice providers should know about the emerging role of HER2- and TROP2-targeted antibody–drug conjugates in NSCLC treatment.

Learning Objectives

Upon completion of this activity, participants should be able to:

Plan individualized treatment strategies for use of approved HER2-targeted ADC therapy in NSCLC, considering current evidence and guidelines, patient factors and preferences, and disease-related factors
Review current clinical trial evidence for targeting TROP-2 in patients with NSCLC with and without actionable genomic alterations

Speakers

Edward B. Garon MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

CE Information

This activity offers 0.5 contact hours (0.5 pharmacology) to attendees.

Accredited by AAPA, ANCC, IPCE.

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until May 11, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosures

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Edward B. Garon, MD, MS

Edward B. Garon, MD, MS: consultant/advisor: AbbVie, Arcus, ArriVent, AstraZeneca, Atreca, Black Diamond, BridgeBio, Bristol Myers Squibb, EMD Serono, Gilead, Hookipa, I-Mab, LianBio, Lilly, Merck, Merus, Novartis, Nuvalent, Pfizer, Regeneron, Sanofi, Seagen, Sensei, Strata, Sumitomo, Summit, Synthekine; researcher: ABL-Bio, ArriVent, AstraZeneca, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Iovance, Lilly, Merck, Mirati, Novartis, Prelude, Regeneron, Synthekine, TILT Biotherapeutics; other financial or material support: A2 Bio, Novartis.

Blanca Ledezma, MSN, NP-AOCNP: consultant/advisor/speaker: AstraZeneca, Lilly.

Denise Rouse, MS, PA-C: consultant/advisor/speaker: Bristol Myers Squibb, Catalyst, Johnson & Johnson, Puma.

Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Back to navigate